Trial Profile
A phase I study to demonstrate the safety and tolerability of oral MNX-200 in metastatic or locally advanced pediatric cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2016
Price :
$35
*
At a glance
- Drugs MNX 200 (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2016 New trial record